Lung Cancer Detection Using PRRX1 and ABCC9 Methylation Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective lung cancer-specific methylation markers for early diagnosis, risk prediction, and prognosis, necessitating the development of novel biomarkers for improved cancer detection and management.
Innovation Solution
Utilization of PRRX1 and ABCC9 genes as methylation markers, specifically detecting CpG island methylation through real-time PCR and sequencing techniques, to diagnose lung cancer with high sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methylation markers are used for cancer diagnosis, then general cancer detection is possible, but lung cancer-specific early diagnosis and risk prediction are insufficient
Solution Approach 1:
The patent applies local quality by identifying and utilizing methylation markers specific to lung cancer (PRRX1 and ABCC9 genes) rather than general cancer markers. This targeted approach enhances the diagnostic precision for lung cancer specifically, addressing the need for disease-specific detection capabilities while maintaining overall diagnostic accuracy.
2Loss of time
If early diagnosis methods are developed, then oncogenesis risk prediction improves, but detection sensitivity and specificity requirements increase complexity
Solution Approach 1:
The patent extracts and focuses on specific methylation markers (PRRX1 and ABCC9 genes) that are highly indicative of lung cancer. By concentrating on these key markers rather than analyzing all possible genetic variations, the method achieves early diagnosis capability with reduced analytical complexity, balancing early detection needs with practical implementation feasibility.
3Measurement precision
If multiple methylation markers are analyzed, then diagnostic comprehensiveness improves, but detection cost and procedural complexity increase
Solution Approach 1:
The patent employs a targeted panel of specific methylation markers (PRRX1 and ABCC9) that can be detected through relatively simple and cost-effective methods. This approach provides comprehensive lung cancer diagnostic information without requiring complex, expensive multi-marker analysis systems, making the detection method more accessible and easier to implement clinically.
Data Source
Figure 1~2
Figure 3A~3B
Figure 4~5
AI summary
The present invention relates to novel use of a paired related homeobox 1 (PRRX1) gene and/or an ATP binding cassette subfamily C member 9 (ABCC9) gene as lung cancer-specific methylation marker(s) and, in particular, to a composition for diagnosing lung cancer by detecting methylation by using the PRRX1 or ABCC9 gene as a biomarker, a kit comprising same, and a method for providing information for lung cancer diagnosis.